Literature DB >> 19587152

Putative novel surface-exposed Streptococcus agalactiae protein frequently expressed by the group B streptococcus from Zimbabwe.

Rooyen T Mavenyengwa1, Johan A Maeland, Sylvester R Moyo.   

Abstract

Group B streptococci (GBS) express a variety of surface-exposed and strain-variable proteins which function as phenotypic markers and as antigens which are able to induce protective immunity in experimental settings. Among these proteins, the chimeric and immunologically cross-reacting alpha-like proteins are particularly important. Another protein, R3, which has been less well studied, occurred at a frequency of 21.5% in GBS from Zimbabwe and, notably, occurred in serotype V strains at a frequency of 75.9%. Working with rabbit antiserum raised against the R3 reference strain ATCC 49447 (strain 10/84; serotype V/R3) to detect the expression of the R3 protein, we recorded findings which suggested that strain 10/84 expressed a strain-variable protein antigen, in addition to R3. The antigen was detected by various enzyme-linked immunosorbent assay-based tests by using acid extract antigens or GBS whole-cell coats and by whole-cell-based Western blotting. We named the putative novel antigen the Z antigen. The Z antigen was a high-molecular-mass antigen that was susceptible to degradation by pepsin and trypsin but that was resistant to m-periodate oxidation and failed to show immunological cross-reactivity with any of a variety of other GBS protein antigens. The Z antigen was expressed by 33/121 (27.2%) of strains of a Zimbabwean GBS strain collection and by 64.2% and 72.4% of the type Ib and type V strains, respectively, and was occasionally expressed by GBS of other capsular serotypes. Thus, the putative novel GBS protein named Z showed distinct capsular antigen associations and presented as an important phenotypic marker in GBS from Zimbabwe. It may be an important antigen in GBS from larger areas of southern Africa. Its prevalence in GBS from Western countries is not known.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19587152      PMCID: PMC2745001          DOI: 10.1128/CVI.00133-09

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  34 in total

1.  Conservation of the C5a peptidase genes in group A and B streptococci.

Authors:  I Chmouryguina; A Suvorov; P Ferrieri; P P Cleary
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

2.  A unique serine-rich repeat protein (Srr-2) and novel surface antigen (epsilon) associated with a virulent lineage of serotype III Streptococcus agalactiae.

Authors:  Kyle N Seifert; Elisabeth E Adderson; April A Whiting; John F Bohnsack; Paula J Crowley; L Jeannine Brady
Journal:  Microbiology       Date:  2006-04       Impact factor: 2.777

Review 3.  Surface proteins of Streptococcus agalactiae and related proteins in other bacterial pathogens.

Authors:  Gunnar Lindahl; Margaretha Stålhammar-Carlemalm; Thomas Areschoug
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

4.  Antigenic determinants of alpha-like proteins of Streptococcus agalactiae.

Authors:  Johan A Maeland; Lars Bevanger; Randi Valsoe Lyng
Journal:  Clin Diagn Lab Immunol       Date:  2004-11

5.  Recombinant group B streptococcus Beta C protein and a variant with the deletion of its immunoglobulin A-binding site are protective mouse maternal vaccines and effective carriers in conjugate vaccines.

Authors:  Hsiao-Hui Yang; Lawrence C Madoff; Hilde-Kari Guttormsen; Yong-Dong Liu; Lawrence C Paoletti
Journal:  Infect Immun       Date:  2007-04-30       Impact factor: 3.441

6.  Distinctive features of surface-anchored proteins of Streptococcus agalactiae strains from Zimbabwe revealed by PCR and dot blotting.

Authors:  Rooyen T Mavenyengwa; Johan A Maeland; Sylvester R Moyo
Journal:  Clin Vaccine Immunol       Date:  2008-07-30

7.  Characterisation of invasive group B streptococci based on investigation of surface proteins and genes encoding surface proteins.

Authors:  E Persson; S Berg; L Bevanger; K Bergh; R Valsö-Lyng; B Trollfors
Journal:  Clin Microbiol Infect       Date:  2007-11-22       Impact factor: 8.067

8.  Recombinant group B Streptococcus alpha-like protein 3 is an effective immunogen and carrier protein.

Authors:  Hsiao-Hui Yang; Samantha J Mascuch; Lawrence C Madoff; Lawrence C Paoletti
Journal:  Clin Vaccine Immunol       Date:  2008-05-07

9.  Serotype IX, a Proposed New Streptococcus agalactiae Serotype.

Authors:  Hans-Christian Slotved; Fanrong Kong; Lotte Lambertsen; Susanne Sauer; Gwendolyn L Gilbert
Journal:  J Clin Microbiol       Date:  2007-07-18       Impact factor: 5.948

10.  Molecular epidemiology and distribution of serotypes, surface proteins, and antibiotic resistance among group B streptococci in Italy.

Authors:  Giovanni Gherardi; Monica Imperi; Lucilla Baldassarri; Marco Pataracchia; Giovanna Alfarone; Simona Recchia; Graziella Orefici; Giordano Dicuonzo; Roberta Creti
Journal:  J Clin Microbiol       Date:  2007-07-18       Impact factor: 5.948

View more
  4 in total

1.  Streptococcus agalactiae alpha-like protein 1 possesses both cross-reacting and Alp1-specific epitopes.

Authors:  Augusta I Kvam; Rooyen T Mavenyengwa; Andreas Radtke; Johan A Maeland
Journal:  Clin Vaccine Immunol       Date:  2011-06-08

2.  Novel aspects of the Z and R3 antigens of Streptococcus agalactiae revealed by immunological testing.

Authors:  Johan A Maeland; Andreas Radtke; Randi V Lyng; Rooyen T Mavenyengwa
Journal:  Clin Vaccine Immunol       Date:  2013-02-13

Review 3.  Survey of immunological features of the alpha-like proteins of Streptococcus agalactiae.

Authors:  Johan A Maeland; Jan E Afset; Randi V Lyng; Andreas Radtke
Journal:  Clin Vaccine Immunol       Date:  2014-12-24

4.  The Streptococcus agalactiae R3 surface protein is encoded by sar5.

Authors:  Adelle Basson; Camilla Olaisen; Linn-Karina Selvik; Randi Valsø Lyng; Hilde Lysvand; Alexandre Gidon; Christina Gabrielsen Aas; Jan Egil Afset; Marte Singsås Dragset
Journal:  PLoS One       Date:  2022-07-29       Impact factor: 3.752

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.